Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Visa Q3 adjusted profit tops estimates on record cross-border volume growth

Visa Q3 adjusted profit tops estimates on record cross-border volume growth

ReutersReuters2026/07/28 20:14
By:Reuters


Overview

  • U.S. digital payments firm's fiscal Q3 net revenue rose 14% yr/yr, driven by volume growth

  • Adjusted EPS for fiscal Q3 beat analyst expectations

  • Company repurchased $4.9 bln in shares during the quarter


Outlook

  • Visa did not provide specific guidance for the current or upcoming periods


Result Drivers

  • VOLUME GROWTH - Co said net revenue growth was driven by increases in payments volume, cross-border volume and processed transactions

  • CROSS-BORDER ACTIVITY - Cross-border volume excluding intra-Europe rose 12% yr/yr, supporting international transaction revenue

  • DATA PROCESSING REVENUE - Data processing revenue increased 17% yr/yr to $6.0 bln, contributing to overall revenue growth


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted EPS

Beat

$3.32

$3.23 (30 Analysts)

Q3 EPS

$2.97


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 42 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the business support services peer group is "buy"

  • Wall Street's median 12-month price target for Visa Inc is $410.00, about 13.1% above its July 27 closing price of $362.53

  • The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 22 three months ago


Reuters Recommended Reads

  • July 28 - Visa to lay off 7% of staff as efficiency push deepens

  • July 28 - PayPal presses on with turnaround in pivotal quarter as sale questions linger

  • July 28 - TransUnion beats Q2 revenue estimates, raises 2026 revenue growth outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales